Envista/$NVST
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Envista
Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.
- Ticker
- $NVST
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 12,000
- Headquarters
- Brea, United States
- Website
- envistaco.com
Envista Metrics
BasicAdvanced
$3.6B
39.57
$0.57
0.86
-
Price and volume
Market cap
$3.6B
Beta
0.86
52-week high
$30.42
52-week low
$18.77
Average daily volume
2.8M
Financial strength
Current ratio
2.425
Quick ratio
1.935
Long term debt to equity
0.504
Total debt to equity
0.516
Interest coverage (TTM)
8.22%
Profitability
EBITDA (TTM)
406.2
Gross margin (TTM)
55.42%
Net profit margin (TTM)
3.33%
Operating margin (TTM)
10.18%
Effective tax rate (TTM)
59.42%
Revenue per employee (TTM)
$240,000
Management effectiveness
Return on assets (TTM)
3.23%
Return on equity (TTM)
3.06%
Valuation
Price to earnings (TTM)
39.574
Price to revenue (TTM)
1.305
Price to book
1.19
Price to tangible book (TTM)
33.32
Price to free cash flow (TTM)
15.028
Free cash flow yield (TTM)
6.65%
Free cash flow per share (TTM)
1.512
Growth
Revenue change (TTM)
11.89%
Earnings per share change (TTM)
84.07%
3-year revenue growth (CAGR)
3.43%
3-year earnings per share growth (CAGR)
-22.40%
What the Analysts think about Envista
Analyst ratings (Buy, Hold, Sell) for Envista stock.
Analyst projections of the future price of Envista stock.
Bulls say / Bears say
Envista delivered 5% core sales growth in Q2, with both segments and all major regions growing. Adjusted EBITDA rose 28% and adjusted EPS 58%, prompting management to raise its 2026 sales, EBITDA and EPS guidance. (PR Newswire)
New products, Spark clear aligners and recent implant acquisitions are supporting share gains and a stronger innovation pipeline. At its September investor day, Envista raised the top end of its medium-term core growth, EBITDA growth and EPS growth ranges. (Stock Analysis, The Motley Fool)
Cash generation and the balance sheet give Envista flexibility to invest, acquire businesses and return capital. Q2 free cash flow was $105 million, net leverage was 0.7 times adjusted EBITDA, and the company repurchased 2.4 million shares during the quarter. (VectorShift Research)
China’s volume-based procurement reforms could cause sharp price cuts in orthodontics and implants during the second half of 2026. Management expects implant prices to fall by roughly 10% to 15%, creating a direct risk to revenue and margins even though the guidance includes the assumed impact. (The Motley Fool, Yahoo Finance)
Reported growth is set to slow in the second half because the fourth quarter has four fewer selling days than the prior-year quarter. Management therefore expects Q4 core growth to be flat to slightly down, leaving less room for execution mistakes against the raised outlook. (The Motley Fool, Yahoo Finance)
Some of the recent growth benefited from non-recurring Spark deferral, channel inventory normalisation and tariff-related pricing actions. Management said underlying growth after removing these effects is closer to 3% to 4%, which may make the longer-term growth story less powerful than headline results suggest. (EarningsCalls.dev)
Data summarised monthly by Lightyear AI. Last updated on 21 Sept 2026.
Envista Financial Performance
Revenues and expenses
Envista Earnings Performance
Company profitability
Upcoming events
No upcoming events
Envista News
AllArticlesVideos
Funds containing Envista
AllUSDGBPEUR
Fund name | Fund size | $NVST weighting |
|---|---|---|
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.11% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.11% |
Xtrackers S&P 500 Swap£XSPX | £3.1B | 0.09% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.06% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.06% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.